The FDA is listening: Integrating the voice of the patient in drug development for Parkinson’s and Huntington’s diseases.
Objective: To present highlights from the Patient-Focused Drug Development (PFDD) meetings held at FDA for Parkinson’s disease (PD) and Huntington’s disease (HD) to raise awareness…Pancreatic polypeptide plasma levels in Parkinson’s disease – a marker of parasympathetic denervation
Objective: To study plasma PP concentration during sham feeding in PD patients and healthy controls, as a measure of pancreatic vagal innervation. Background: Most patients…Neurogenic Orthostatic Hypotension Burden of Illness Patient and Caregiver Survey: Impact of Symptoms
Objective: To determine the impact of neurogenic orthostatic hypotension (nOH) on the quality of life (QoL) of patients with autonomic dysfunction and the burden on…Heart rate variability in Parkinson’s Disease and idiopathic REM sleep behavior disorder and relation with other non-motor symptoms
Objective: To evaluate Heart Rate Variability (HRV) changes across sleep stages in Parkinson's Disease (PD) and idiopathic REM Sleep Behavior disorder (RBD) patients, and to…Patient-Reported Outcomes in a Prospective Real-World Study of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension
Objective: To assess the effect of droxidopa treatment on function, depression, and health-related quality of life (HRQoL) in patients with neurogenic orthostatic hypotension (nOH). Background:…Assessment of Autonomic Dysfunction in Parkinson’s Disease
Objective: Assessment of autonomic dysfunction in patients with Parkinson's disease and further comparison with patients without autonomic symptoms Background: A frequent disabling complication of Parkinson’s…Combined Surgical Therapies for Optimal Management of Advanced Parkinson’s Disease
Objective: We report a case of a patient with advanced PD who began LCIG for refractory motor fluctuations while continuing longstanding STN-DBS. Background: LCIG and…Association of impaired melatonin secretion with sleep disturbance in Parkinson’s disease
Objective: To clarify if impaired melatonin secretion is associated with daytime or nighttime sleep disturbances in patients with Parkinson’s disease (PD). Background: PD is associated…Listen to your heart: ordinal pattern statistics reveal altered cardiac rhythm dynamics in LRRK2-nonmanifesting carriers
Objective: To assess the complexity of heart rate variability (HRV) dynamics in LRRK2-nonmanifesting carriers compared to healthy individuals. Background: Cardiovascular autonomic dysfunction is an early…Real-world non-motor score changes in Parkinson’s disease patients with motor fluctuations: The J-FIRST study
Objective: To identify changes in non-motor symptoms (NMSs) over time in Japanese Parkinson’s disease (PD) patients without dementia exhibiting motor fluctuations. Background: PD can cause…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 27
- Next Page »
